Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
Pneumococcal vaccine
Merck Sharp & Dohme Ireland (Human Health) Limited
J07AL; J07AL01
Pneumococcal vaccine
25mcg/0.5 millilitre(s)
Solution for injection
Product subject to prescription which may not be renewed (A)
Pneumococcal vaccines; pneumococcus, purified polysaccharides antigen
Not marketed
2001-05-04
PACKAGE LEAFLET: INFORMATION FOR THE USER PNEUMOVAX® 23 SOLUTION FOR INJECTION IN A VIAL Pneumococcal Polysaccharide Vaccine For adults and children 2 years and above. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD RECEIVE THIS VACCINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have further questions, please ask your doctor or your pharmacist. • This vaccine has been prescribed for you or your child. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours or your child's. • If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What PNEUMOVAX 23 is and what it is used for 2. What you need to know before you or your child use PNEUMOVAX 23 3. How to use PNEUMOVAX 23 4. Possible side effects 5. How to store PNEUMOVAX 23 6. Contents of the pack and other information 1. WHAT PNEUMOVAX 23 IS AND WHAT IT IS USED FOR PNEUMOVAX 23 is a pneumococcal vaccine. Vaccines are used to protect you or your child against infectious diseases. Your doctor has recommended that you or your child (two years of age and older) have the vaccine to help protect against severe infections caused by bacteria that are called pneumococci. Pneumococci can cause infections of the lungs (especially pneumonia) and of the coverings over the brain and spinal cord (meningitis) and in the blood (bacteraemia or septicaemia). The vaccine will only be able to protect you or your child against pneumococcal infections that are due to the types of these bacteria that are included in the vaccine. However, the 23 pneumococcal types in the vaccine include those that cause almost all (about nine out of ten) infections caused by pneumococci. When the vaccine is given to you or your child, the body’s natural defences make antibodies that help to protect against pneumococcal infections. Pneumoc Διαβάστε το πλήρες έγγραφο
Health Products Regulatory Authority 15 December 2022 CRN00D9SH Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT PNEUMOVAX 23 solution for injection in a vial Pneumococcal Polysaccharide Vaccine 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F. Excipient(s) with known effect Sodium less than 1 mmol (23 mg) per dosage unit. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection in a vial. The vaccine is a clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS PNEUMOVAX 23 is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults. See section 5.1 for information on protection against specific pneumococcal serotypes. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The immunisation schedules for PNEUMOVAX 23 should be based on official recommendations. POSOLOGY Primary vaccination: Adults and children of 2 years of age or older- one single dose of 0.5 millilitre by intramuscular or subcutaneous injection. PNEUMOVAX 23 is not recommended for use in children below 2 years of age as the safety and efficacy of the vaccine have not been established and the antibody response may be poor. Special dosing: It is recommended that pneumococcal vaccine should preferably be given at least two weeks before elective splenectomy or the initiation of chemotherapy or other immunosuppressive treatment. Vaccination during chemotherapy or radiation therapy should be avoided. Following completion of chemotherapy and/or radiation therapy for neoplastic disease, immune responses to vaccination may remain diminished. The vaccine should not be administered any sooner than three months after completion of such therapy. A longer delay may be appropriate for patients who have received intensiv Διαβάστε το πλήρες έγγραφο